Objective-The calcium composition of atherosclerotic plaque is thought to be associated with increased risk for cardiovascular events, but whether plaque calcium itself is predictive of worsening clinical outcomes remains highly controversial. Inflammation is likely a key mediator of vascular calcification, but immune signaling mechanisms that promote this process are minimally understood. Approach and Results-Here, we identify Rac2 as a major inflammatory regulator of signaling that directs plaque osteogenesis. In experimental atherogenesis, Rac2 prevented progressive calcification through its suppression of Rac1-dependent macrophage interleukin-1β (IL-1β) expression, which in turn is a key driver of vascular smooth muscle cell calcium deposition by its ability to promote osteogenic transcriptional programs. Calcified coronary arteries from patients revealed decreased Rac2 expression but increased IL-1β expression, and high coronary calcium burden in patients with coronary artery disease was associated with significantly increased serum IL-1β levels. Moreover, we found that elevated IL-1β was an independent predictor of cardiovascular death in those subjects with high coronary calcium burden. Conclusions-Overall, these studies identify a novel Rac2-mediated regulation of macrophage IL-1β expression, which has the potential to serve as a powerful biomarker and therapeutic target for atherosclerosis. 
I schemic heart disease caused by atherosclerosis remains the single leading cause of morbidity and mortality in the world. 1 Traditional risk factor assessment, using sex, age, race, lipid profile, blood pressure, smoking, and diabetes mellitus, is commonly used to risk stratify individuals with unestablished disease. 2 When applied to a diverse patient population, however, current risk assessment calculators can often overestimate risk in both men and women, resulting in substantial implications for the health care of individuals and to the cost of the healthcare system in general. 3 
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Coupling traditional risk assessment to a patient vulnerability bioprofile, using specific biomarkers, and structural information about plaque composition may enhance our ability to achieve improved risk stratification, moving cardiology toward an era of precision medicine. [4] [5] [6] One such example of plaque assessment is calcification, a widely studied pathological finding that is thought to provide predictive values in terms of total atherosclerotic burden and risk of cardiovascular mortality and of all-cause mortality. 7, 8 Somewhat paradoxically, there has been a growing body of literature demonstrating that certain types of densely calcified plaques are associated with more stable disease. [8] [9] [10] [11] [12] [13] In sum, these clinical studies highlight the potential value in defining mechanistic determinants of plaque calcium composition to better assess risk, but whether therapeutic modulation of the biological processes that regulate plaque calcification might modify cardiovascular event risk will need to be determined.
Systemic inflammation as measured by high-sensitivity C-reactive protein is an example of a well-established patient vulnerability factor that has predictive value in terms of cardiovascular events.
14 Although inflammation, in general, can be associated with the formation of vascular calcification, Moreover, there is significant controversy over whether inflammation and calcification work independently to promote increased event risk in patients or whether they are capable of working synergistically to promote increased risk. [20] [21] [22] Rac1 and Rac2 are key signal transducers in inflammatory cells, and Rac-based signaling influences the expression of several growth factors and cytokines. [23] [24] [25] [26] [27] Recently, we determined that Rac2 deletion in macrophages led to reduced VEGF-A (vascular endothelial growth factor A) expression and consequent defects in inflammatory arteriogenesis in response to ischemia. 26 During our investigation, we identified that Rac2 deletion also led to basal elevations in activated (GTP bound) Rac1. Activated Rac1 can promote nuclear factor-κB (NF-κB) signaling and reactive oxygen species (ROS) production via nicotinamide adenine dinucleotide phosphate oxidase, both known activators of the NACHT, LRR, and PYD domains-containing protein 3 inflammasome protein complex that promotes interleukin-1β (IL-1β) maturation. 24, 28, 29 We hypothesized that though the angiogenic macrophage responses were negatively affected by the Rac2 deletion, certain inflammatory macrophage responses may in fact be upregulated. Here, we identify Rac2 as a critical determinant of the extent of macrophage Rac1-dependent IL-1β expression and consequent IL-1β-mediated atherosclerotic calcification. We demonstrate the robust efficacy of IL-1β inhibition in ameliorating experimental atherosclerosis. Most importantly, we identify a key correlation between elevated IL-1β serum levels and cardiovascular deaths in subjects with high vascular calcium burden. Overall, our findings highlight the importance of Rac2-mediated IL-1β suppression in regulation of vascular calcification and identify mechanistic basis for therapeutically targeting IL-1β in clinical atherosclerosis.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Calcified Plaque Is Associated With Increased IL-1β and Decreased Rac2 Expression
ApoE
−/− mice were fed a high-fat diet (HFD) to determine the relationship between Rac1 and Rac2 expression and plaque calcification. Near-infrared conjugated bisphosphonate compounds can bind to hydroxyapatite deposited by osteoblast-like cells during the mineralization of calcium, allowing for ex vivo molecular imaging and quantification of the calcification process. 30, 31 We found a modest increase in aortic calcification ≤14 weeks after start of HFD, but between 14 and 21 weeks, there was a dramatic increase ( Figure 1A and 1B). To begin investigating the role of Rac proteins in this context, Rac1 and Rac2 expression were assessed using RNA from the aortic arch. Initially, the hematopoietic-specific Rac2 expression rose in a manner corresponding to the influx of macrophages (as determined by F4/80), but at 21 weeks, Rac2 expression decreased despite sustained F4/80 expression ( Figure 1C ). These changes in the expression were limited to Rac2, as Rac1 expression was minimally altered over time. IL-1β expression trended toward a modest increase until 14 weeks, and between 14 and 21 weeks, there was a significant increase that mirrored the rise in calcification.
To validate these findings in human atherosclerosis, we analyzed Rac expression using coronary samples from explanted human hearts of patients undergoing orthotopic heart transplant for ischemic cardiomyopathy. Left anterior descending coronary artery segments (1 cm) from the recently explanted human hearts were divided into 2 groups (calcified versus noncalcified) based on the presence of calcium identified by noncontrast computed tomographic imaging using the Agatston method, 32 attenuation coefficient of >130 Hounsfield Units with an area of 3 or more pixels ( Figure 1D ). Neointimal plaque lesion area and calcification were confirmed by Elastic Van Gieson staining of histological sections from the plaque ( Figure 1E ). We found comparable degrees of neointimal plaque burden in the 2 groups as assessed by measurement of the intima:media (I:M) thickness ratio ( Figure 1E and 1F ), but the groups differed in terms of the presence or absence of plaque calcification. Interestingly, consistent with the calcified atherosclerosis of the mouse model, the relative Rac2 mRNA expression was significantly reduced in the human coronary segments containing calcified plaque, whereas Rac1 expression and macrophage marker, CSF1R (CD115), expression remained constant ( Figure 1G through 1I ). Of note, IL-1β expression was found to be significantly increased in the coronary artery segments containing calcified plaque in a manner consistent with the animal model ( Figure 1J ). 
Rac2 Deletion Does Not Affect Serum Cholesterol or Plaque Lipid Composition
Rac2 Deletion Leads to Increased Plaque Calcification
To define the role of Rac2 in vascular calcification, we analyzed plaque calcification by a combination of imaging and histology. Microcomputed tomographic imaging demonstrated hypoattenuated lesions in the aortic sinuses and the lesser curvature of the aortic arches from Rac2 Figure 3C ). In sum, both the increased calcification phenotype and the protection from the phenotype were attributable to Rac2 function in the hematopoietic compartment, and calcification remained associated with elevated serum IL-1β.
Rac2 Deletion Leads to Increased Macrophage IL-1β Expression
To identify specific signals regulated by Rac proteins that are critical to promoting the progressive calcification, cytokine mRNA profiling was performed on aortic arch tissues. Among multiple cytokines tested, IL-1β was the only factor that was significantly increased in the Rac2 −/− ApoE −/− aortas relative to the Rac2 +/+ ApoE −/− aortas ( Figure 3D ). To assess whether the increase in IL-1β mRNA expression in calcified plaque reflected elevations in mature secreted IL-1β protein, we measured IL-1β protein from the serum. Systemic IL-1β concentrations were significantly higher in the Rac2 −/− ApoE −/− mice on HFD, whereas IL-1α and tumor necrosis factor-α (TNF-α) concentrations did not differ significantly ( Figure 3E ). Figure 4D ).
There are several signaling pathways (eg, NF-κB, nicotinamide adenine dinucleotide phosphate-induced ROS) that may be upstream of inflammasome activation and IL-1β mRNA expression. increase of NF-κB activation in response to lipopolysaccharide-primed cholesterol crystal exposure ( Figure 4E ). In addition, Rac2 −/− ApoE −/− BMDMs revealed higher ROS production ( Figure 4F ). To define the role of NF-κB and ROS production in the expression of IL-1β, BMDMs were stimulated to produce IL-1β in the presence or absence of an NF-κB inhibitor (celestrol) and an inhibitor of ROS production (diphenyleneiodonium). Both inhibitors decreased IL-1β protein secretion through reduced mRNA expression ( Figure 4G and 4H) , whereas a p38-mitogen-activated protein kinase inhibitor, SB203580, had no effect on IL-1β expression (Figure 4G and 4H; Figure III in the online-only Data Supplement). In sum, Rac2 deletion resulted in increased NF-κB activation and increased production of ROS, and macrophage IL-1β expression was dependent on these 2 signaling effectors.
Rac2 Suppresses IL-1β Expression Via Inhibition of Rac1 Activity
Rac1 can promote activation of NF-κB and production of ROS via nicotinamide adenine dinucleotide phosphate oxidase, both leading to inflammasome activation and IL-1β production. 24, 28, 29 To determine the influence of Rac2 deletion on Rac1, we first explored the expression patterns of Rac1 and Rac2 in atherosclerotic plaque. Rac2 expression in atherosclerotic plaques from Rac2 +/+ ApoE −/− mice was primarily limited to CD68
+ cells relative to SMA + cells ( Figure 5A and 5B). mice after BMDMs were transfected with GFP (green fluorescent protein) alone (control) or GFP with wild-type Rac2 (Rac2) or with constitutively active Rac2 (Q61L). C, BMDMs, transfected as in B, were primed with LPS and treated with 1000 μg/mL cholesterol crystals for 24 h, and ELISA for IL-1β was performed on culture supernatants (**, P<0.05; n=3 animals with each animal data point being an average of 3 technical repeats). D, Real-time polymerase chain reaction (PCR) quantification of IL-1β mRNA isolated from resting or LPS-primed BMDMs that were treated with 1000 μg/mL cholesterol crystals for 24 h (**, P<0.05; n=3 animals with each animal data point being an average of 3 technical repeats). E, Relative luciferase activity in Rac2 
ApoE
−/− BMDM lysates demonstrated significantly increased levels of GTP-Rac1 both at baseline and in a GTPγS dose-dependent manner ( Figure 5E and 5F). Taken in sum, Rac2 expression seemed limited to macrophages, whereas Rac1 was expressed in both macrophages and smooth muscle cells, and Rac2 deletion led to increased Rac1 activity despite having no effect on Rac1 expression.
To determine whether Rac1 activity was important in the elevated IL-1β expression associated with calcification in our model, we treated Rac2 −/− ApoE −/− BMDMs with 
Rac1
fl/fl mice pretreated with or without 4-hydroxytamoxifen (4-OHT) were exposed to 1000 μg/mL cholesterol crystals for 24 h, and Enzyme-linked immunosorbent assay (ELISA) for IL-1β was performed on culture supernatants (**, P<0.05; n=3 animals with each animal data point being an average of 3 technical repeats). Lower, Rac1 and actin immunoblots of BMDM lysates. All data are representative of at least 3 independent experiments. Quantitative data are displayed as mean±SEM. GDP indicates guanosine diphosphate; I, intimal lesion; L, lumen; and M, media.
an established Rac1 inhibitor (EHT 1864), 35 which led to a dose-dependent decrease of IL-1β production ( Figure 5G ). To exclude the possibility of destabilized cytoskeletal mobility by EHT 1864, 35 we assessed whether this reduction in IL-1β production was because of reduced phagocytosis of cholesterol crystals. We found no significant difference in the phagocytosis of cholesterol crystals in Rac2 
fl/fl mice demonstrated normalization of IL-1β protein expression, supporting the Rac1 dependence of increased IL-1β with Rac2 deletion. In sum, both Rac1 inhibition and Rac1 deletion led to a loss in the enhanced IL-1β production conferred by the Rac2 deletion.
Macrophage IL-1β Targets Vascular Smooth Muscle Cells to Promote Vascular Calcification
Inflammatory stimuli like lipopolysaccharide, TNF-α, or ROS can stimulate mesenchymal cells to mineralize calcium, but whether IL-1β plays a role in this process is somewhat controversial. 15, 36, 37 To assess whether Rac2 gene ) that were treated with increasing concentrations of IL-1β for 21 days (**, P<0.05; n=6 animals with each animal data point being an average of 3 technical repeats). Scale bar 1000 μm. C, Real-time polymerase chain reaction quantification of runt-related transcription factor 2 (RUNX2), Sry-related HMG box 9 (SOX9), osterix (OSX), Msh homeobox 2 (MSX2), and alkaline phosphatase (ALP) in mRNA samples isolated from primary mouse aortic smooth muscle cells (ApoE
−/−
) that were treated with 0 or 100 pg/mL of recombinant IL-1β for 21 days (**, P<0.05; n=6 animals with each animal data point being an average of 3 technical repeats). D, Near-infrared calcium imaging along with quantification (E) of calcification signal in ex vivo aortas from Rac2 −/− ApoE −/− mice after high-fat diet (HFD) for 9 weeks to establish baseline and then after an additional 5 weeks of HFD coupled to treatment with vehicle control or IL-1 receptor antagonist (IL-1ra; **, P<0.05; n=8 animals). F, Serum IL-1β protein concentrations by Enzyme-linked immunosorbent assay (ELISA) (**, P<0.05; n=8 animals). G, Hematoxylin and eosin staining of adjacent aortic sinus sections at the level of the aortic valve after HFD for 9 weeks to establish baseline and then after an additional 5 weeks of HFD coupled to treatment with vehicle control or IL-1ra. Bar, 200 μm. H, Quantification of average aortic plaque area (**, P<0.05; n=9 aortic valve sinuses from 3 animals). All data are representative of at least 3 independent experiments. Quantitative data are displayed as mean±SEM.
deletion affects smooth muscle cell expression of IL-1β, we cultured primary MASMCs and performed inflammasome stimulation with lipopolysaccharide (10 ng/mL) followed by cholesterol crystal exposure (1000 μg/mL). BMDMs were used as a positive control for the expression of IL-1β. Using BMDMs as a control for the assay, MASMCs did not express detectable levels of IL-1β in response to lipopolysaccharide-coupled cholesterol crystal exposure nor were there any increases in IL-1β expression attributable to Rac2 gene deletion ( Figure VI in the online-only Data Supplement). To determine whether MASMCs might play a more responsive role to IL-1β, MASMCs from ApoE −/− mice were incubated with increasing concentrations of IL-1β and exhibited a dose-dependent response in terms of calcification ( Figure 6A and 6B) . Moreover, consistent with our findings in the aortic plaques, MASMCs incubated in the presence or absence of IL-1β revealed increased expression of the osteogenic transcription factors, runt-related transcription factor 2, Sry-related HMG box 9, osterix, and Msh homeobox 2, and the osteoblast marker, alkaline phosphatase ( Figure 6C ).
Calcification Is Dependent on IL-1β Signaling
To determine whether the increased calcification found in Rac2 −/− ApoE −/− mice was, in fact, dependent on the increased expression of IL-1β, we inhibited IL-1 signaling using treatment with the IL-1 receptor antagonist (IL-1ra, anakinra; Figure VII in the online-only Data Supplement). Treatment with IL-1ra prevented progression of calcification and revealed a modest trend toward calcific regression during the treatment period ( Figure 6D and 6E) . Consistent with previous studies, 38 treatment with IL-1ra reduced systemic IL-1β protein levels as measured by Enzyme-linked immunosorbent assay on serum samples ( Figure 6F ). IL-1ra also prevented expansion of sinus plaque area ( Figure 6G and 6H) . These findings confirm a cause-effect relationship between the increased IL-1β expression and the progressive atherosclerotic calcification.
Increased Serum IL-1β Level Is a Key Predictor of Cardiovascular End Points in Human Coronary Artery Disease
To define the relationship between IL-1β protein levels and degree of atherosclerotic calcification, we identified a patient Figure 7 . Increased serum interleukin-1β (IL-1β) level is associated with higher coronary calcium burden and is predictive of cardiovascular outcomes in patients. A, The Pearson correlation between IL-1β protein concentrations and coronary artery calcium scoring (CACS; ***, P=0.001; n=79). B, Noncontrast computed tomographic scan images illustrating the left anterior descending territory calcification in coronary disease patients who were divided by CACS into low and high calcium burden groups. Bar, 3 cm. C, Serum IL-1β protein concentrations for each patient (gray dots) along with median and interquartile ranges within each level of calcium burden (***, P=0.0040; n=39-40). D, Kaplan-Meier event curve for hard cardiac events of sudden cardiac death, myocardial infarction, and acute coronary syndrome in patients divided by calcium burden (**, P=0.0259, n=39-40, log-rank test). E, Kaplan-Meier event curve for hard cardiac events of sudden cardiac death, myocardial infarction, and acute coronary syndrome in patients divided by both calcium burden and serum IL-1β concentration (**, P=0.0119, n=10-28, log-rank test).
population with chronic stable coronary heart disease who underwent baseline blood draw for serum sample analysis and non-ECG-gated, noncontrast chest computed tomography to allow for coronary artery calcium scoring. Serum IL-1β protein concentrations positively correlated with coronary artery calcium scoring ( Figure 7A ). Patients were divided into 2 groups (low and high calcium burden) based on the coronary artery calcium scoring from the chest computed tomography ( Figure 7B ; Table for patient demographics). There were no significant differences between the groups in terms of cardiac risk factors, including age, hypertension, hyperlipidemia, diabetes mellitus, smoking, family history, and previous myocardial infarctions. There was a trend toward increased previous revascularization history in the high calcium burden group that did not meet statistical significance. Interestingly, we found a significantly higher median concentration of IL-1β in the high calcium burden group, supporting a strong clinical association between IL-1β levels and calcium burden (Table; Figure 7C ).
To further elucidate the relevance of IL-1β levels and calcification on clinical outcomes, we assessed the frequency of cardiovascular events (sudden cardiac death, myocardial infarction, and acute coronary syndrome) between the 2 groups ( Figure 7D ). There was a significantly increased hazard ratio in the high calcium burden group (4.88; 95% confidence interval, 1.03-22.98; P=0.045). There was a total of 10 events: 6 sudden cardiac deaths, 1 ST segment elevation myocardial infarction, 2 non-ST segment elevation myocardial infarctions, and 1 acute coronary syndrome. The differences between the 2 groups were primarily driven by sudden cardiac death. Next, we determined whether serum IL-1β level can serve as a further prognostic factor in these subjects. Both the low and high calcium burden groups were further subdivided into IL-1β ≤1.8 pg/mL and IL-1β >1.8 pg/mL groups based on the median IL-1β concentration in the low calcium burden group ( Figure 7E) . We found that all of the cardiovascular events in both the low (n=2) and high (n=8) coronary artery calcium scoring groups occurred in subjects with elevated IL-1β levels, further implicating a key role for elevated IL-1β level as a prognostic indicator for worsening cardiovascular outcomes in individuals with established coronary artery disease.
Discussion
Calcification of atherosclerotic plaque is common in human disease, has been identified as a marker of disease burden, and is associated with risk of cardiovascular events. 7, 8 Recent data have demonstrated that the composition of calcium within individual plaques may predict vulnerability in some situations whereas stability in others, indicating that there are likely additional factors that couple with calcification to alleviate or worsen risk. [8] [9] [10] [11] 39 Inflammation is associated with calcification in animal models of disease, but there is ongoing debate as to whether inflammation can couple with calcification (ie, inflammatory calcification) to promote increased cardiovascular event risk in patients. [15] [16] [17] [18] [19] [20] [21] [22] We have identified a novel, inflammatory signaling axis that relies on Rac2 to modulate the level of Rac1-dependent macrophage IL-1β expression, which consequently determines extent of atherosclerotic calcification ( Figure 8 ).
The expression of Rac2 in macrophages was dynamic, rising with acute inflammation to dampen the immune response, as in the early atherogenesis in the ApoE −/− model or in the early macrophage responses to lipopolysaccharide, but over time Rac2 expression returns toward a baseline, allowing for enhanced IL-1β expression in the setting of chronic inflammation. This enhanced IL-1β expression was modeled quite well by the Rac2 deletion animals. The role of Rac2 deletion in inflammatory, progressive atherosclerotic calcification was independent of lipid burden, as the atherosclerotic plaque lipid and the total serum cholesterol and low-density lipoprotein levels were unaffected. Comparable macrophage recruitment to atherosclerotic plaque indicated that Rac2 is essentially dispensable for macrophage migration and localization to plaque in vivo. However, Rac2 deficiency did change the calcium composition of the plaque, and moreover, Rac2 was found to be a major determinant for the degree of macrophage IL-1β expression. The differences in macrophage IL-1β expression conferred by Rac2 gene deletion were directly dependent on Rac1, as demonstrated by studies using both pharmacological or genetic abrogation of Rac1 signaling. The elevation of Rac1 activity in the setting of Rac2 gene deletion is consistent with previous reports describing a compensatory relationship between Racs that results from complementary (albeit with some distinctions) roles in migration and activation of nicotinamide adenine dinucleotide phosphate oxidase complex in myeloid cells. 23, [40] [41] [42] However, here, we are able to define a novel, antagonistic relationship between Rac2 and Rac1 with regard to the signaling that regulates the expression of IL-1β. Further elucidation of the mechanisms behind this antagonistic relationship (ie, competition for a common guanine nucleotide exchange factor) will be an important future direction of this work.
Both the bone marrow transplant data and the data confirming that CD68 + cell populations express IL-1β in the plaques demonstrated a major role for the hematopoietic compartment, and more specifically macrophages, in our vascular calcification phenotype. In our study, MASMCs seemed to play an important responsive role to the IL-1β expressed by macrophages through the increased expression of osteogenic markers and enhanced calcium deposition. There is precedent for this responsiveness of vascular mesenchymal cells in several important early studies that have demonstrated that in vitro calcifying vascular cells can express osteoblast-like markers such as alkaline phosphatase in response to inflammatory stimuli, including lipopolysaccharide, TNF-α, or ROS. 15, 36 Moreover, there have been several outstanding studies of the vascular mesenchymal cell inflammatory response, which involves formation of matrix vesicles, plasma membrane-derived extracellular bodies and known to exhibit the proteins, matrix metalloproteinases, and phospholipids necessary for calcium mineralization, at the nidus of calcification. 15, 16 Recently, the protein, sortilin, has been shown to facilitate loading of the calcium mineralizing enzyme, alkaline phosphatase, into such extracellular vesicles to promote mesenchymal-driven calcification. 43 A close association between inflammatory macrophages and calcifying vascular cells seems to be required and in some studies involves either macrophage-secreted factors like TNF-α or cell-cell contact through as yet unclear mechanisms to promote vascular calcification. 15, 18, 19 Previous studies have largely attributed activation of osteogenic gene programing to TNF-α, making the critical role of IL-1β in our model novel. 19, 36, 44 IL-1β has been established as important to early atherogenesis as an intermediary between lipid metabolism and activation of the immune system, but its role in calcific progression had remained somewhat controversial and unclear. 37, 45 Recently, a study of IL-1ra gene deletion demonstrated consequent increased aortic valve thickness that was associated with elevated TNF-α expression and that was abrogated by concomitant TNF-α gene deletion, supporting overlapping influence or possible interdependence of the 2 cytokines. 46 Yet in our study, TNF-α expression was not significantly altered as a result of the Rac2 gene deletion. Given our finding of increased osteogenic transcription factor expression, including runt-related transcription factor 2, Sry-related HMG box 9, osterix, and Msh homeobox 2, from plaque tissue, our study raises the question of possible direct mechanism of IL-1 receptor signaling in the promotion of an osteogenic program in mesenchymal cells, and this will be an important future area of study.
Our in vivo studies using IL-1ra further demonstrate the causative role of IL-1β as a major determinant for the degree of plaque calcification. The retrospective analysis of our patient population with stable coronary disease reinforces the role of increased IL-1β in human vascular calcification. Most importantly, we provide pivotal clinical evidence that the combination of elevated IL-1β and high calcium burden was associated with worsened cardiovascular outcomes, indicating that elevated IL-1β levels in the setting of increased vascular calcification can serve as a critical determinant of plaque stability. Few clinical studies have demonstrated an association between measures of IL-1β and atherosclerotic burden, and to date, no studies have clearly evaluated the association between IL-1β and atherosclerotic calcification or cardiovascular outcomes. [47] [48] [49] Although we acknowledge that further study is required because our sample size is small and our study analysis is retrospective, no previous studies to date have demonstrated such a promising prognostic relevance for increased IL-1β levels with worsening outcomes in coronary artery disease. 47, [49] [50] [51] IL-1β inhibitory antibody (canakinumab) therapy is under evaluation for the reduction of secondary events in patients with ongoing inflammation after myocardial infarction. 52 Our mechanistic study outlines a critical signaling mechanism that provides fundamental understanding of the rationale for targeting this pathway as we attempt to bring treatment of cardiovascular patients into the era of precision medicine.
In summary, our findings demonstrate that the Rac2 expression is a key regulator of macrophage IL-1β expression and the consequent progressive calcification of atherosclerotic lesions. We anticipate that this line of study will lead to the development of novel, Rac-targeted therapeutic strategies that modulate plaque calcium composition to improve outcomes in individuals with coronary artery disease.
